AtriCure receives regulatory approval to sell AtriClip devices in China

AtriCure announced that it has received regulatory approval from the National Medical Products Administration NMPA of China to market and sell several models of its AtriClip Left Atrial Appendage , LAA, Exclusion System. The AtriClip device is an innovative solution designed to exclude and electrically isolate the left atrial appendage during cardiac surgery. The LAA is a major source of blood clots in patients with Afib, and this approval marks a significant milestone in AtriCure’s mission to provide life-saving treatments for patients suffering from Afib and associated risks.